Between now and November most buyers will have a reassuring conversation with every supplier they use. Reassurance is not a document, and in a definitional change the document is what matters.
These are the questions worth asking, and the ones where a verbal answer is not sufficient.
1. Which standard do your certificates report against?
Section 781 of Public Law 119-37 moves the hemp test to “total tetrahydrocannabinols concentration (including tetrahydrocannabinolic acid)” from 12 November 2026. A COA reporting delta-9 against 0.3 percent answers the previous question correctly and the new question not at all.
Get in writing: confirmation of the reporting standard, and a commitment to issue total-THC documentation, with a date and a lot number from which it applies.
2. What is the residual cannabinoid content, as a number?
The finished-product cap is 0.4 mg combined total per container across THC and other cannabinoids with similar or similarly marketed effects. Residual cannabinoid content in aromatic inputs consumes that budget.
“Negligible” is not a number. Neither is “below detection limit” without the detection limit stated.
Get in writing: a figure, the analytical method, and the panel scope.
3. How wide is the cannabinoid panel?
A THC-only panel cannot tell you whether a product meets a combined cap that reaches other cannabinoids. This is the same interpretive discipline we apply to aromatic analysis in reading GC-MS data: know what the method was actually looking for before you trust what it did not find.
Get in writing: the analyte list.
4. What is your batch-to-batch variance on this profile?
If a reformulated product carries its aromatic profile without a cannabinoid, consistency becomes the customer’s direct experience. A supplier who has never been asked this will not have it to hand, which is itself informative.
Get in writing: variance data across several recent lots, not a specification range. A spec range is a promise. Lot data is evidence.
5. What happens if a jurisdiction makes this material unsaleable?
The contractual question, and the one most likely to be answered with a shrug. Regulatory change, force majeure, termination rights, and what happens to committed volume and any inventory you are holding.
Get in writing: the clause. If there is not one, that is the negotiation, and it is much easier in August than in November. The commercial architecture behind this sits in the sourcing playbook.
6. Can you support a reformulation, or only fulfil an order?
These are different relationships. A catalogue supplier ships what is on the list. A formulation partner helps you rebuild a profile when the payload changes.
Most brands making this transition need the second and are contracted with the first. Custom formulation partners and cGMP-compliant suppliers are the shortlist worth building now.
7. What is your own supply concentration?
Ask where their material comes from. A supply chain optimised purely on price tends to concentrate geographically, and concentrated chains fail together when a jurisdiction moves.
Get in writing: at minimum, whether single-source dependencies exist for the profiles you rely on.
The one that is not a question
Qualify a second source for anything critical. It takes longer than people expect, because moving from a sample to production scale is a process rather than a purchase, and starting it in October means it completes in the new year.
The full evaluation framework is in our 12-point supplier checklist. What November adds is urgency and two new documentation questions, not a different method.
About this brief
Written 29 July 2026 and checked against the statute and the Federal Register rather than against secondary coverage. This is a summary for commercial planning, not legal advice. Where the answer depends on your product format, your state or your licence position, take the specific question to your own counsel.
